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We have isolated artificial ligands or aptamers for
infectious prions in order to investigate conformational
aspects of prion pathogenesis. The aptamers are 2-
fluoro-modified RNA produced by in vitro selection from
a large, randomized library. One of these ligands
(aptamer SAF-93) had more than 10-fold higher affinity
for PrPSc than for recombinant PrPC and inhibited the
accumulation of PrPres in near physiological cell-free
conversion assay. To understand the molecular basis of
these properties and to distinguish specific from non-
specific aptamer-PrP interactions, we studied deletion
mutants of bovine PrP in denatured, -helix-rich and
-sheet-rich forms. We provide evidence that, like
scrapie-associated fibrils (SAF), the -oligomer of PrP
bound to SAF-93 with at least 10-fold higher affinity
than did the -form. This differential affinity could be
explained by the existence of two binding sites within
the PrP molecule. Site 1 lies within residues 23–110 in
the unstructured N terminus and is a nonspecific RNA
binding site found in all forms of PrP. The region be-
tween residue 90 and 110 forms a hinge region that is
occluded in the -rich form of PrP but becomes exposed
in the denatured form of PrP. Site 2 lies in the region
C-terminal of residue 110. This site is -sheet conforma-
tion-specific and is not recognized by control RNAs.
Taken together, these data provide for the first time a
specific ligand for a disease conformation-associated
site in a region of PrP critical for conformational con-
version. This aptamer could provide tools for the further
analysis of the processes of PrP misfolding during prion
disease and leads for the development of diagnostic and
therapeutic approaches to TSEs.
A simple observation that emerges from the examination of
the structures of all mammalian recombinant PrPs1 that have
been solved so far in their -helix-rich forms is that they have
a highly positively charged N-terminal tail that is flexibly
disordered and a stable globular C-terminal domain (1–10). It
is becoming clear that these structural features must have
some functional significance. Indeed, there is increasing evi-
dence that PrP may accomplish its as yet unknown physiolog-
ical function by allowing both the structured C-terminal do-
main and the unstructured N-terminal part to interact with a
variety of ligands.
The C-terminal domain seems to interact with a protein X
that is thought to feature in the conversion of PrPC into PrPSc
by acting like a molecular chaperone in facilitating the unfold-
ing of PrPC and its refolding into nascent PrPSc (11, 12). Protein
X appears to bind to the side chains of residues 165–171 that
form a loop and to residues on the surface of helix C that lie
between the disulfide bond and the C terminus (12).
The unstructured N-terminal part of PrP can interact with a
variety of molecules. Metal binding of PrP resides primarily in
an octapeptide repeat motif between residues 53 and 93 (13).
Although a more distal site has also been proposed (14), there
seems to be a connection between metal-binding status and the
conformation of PrP (15–17). Sulfated glycans interact with
PrP (18) of which heparin and heparan sulfate have been
shown to have three broad binding sites: residues 23–52, 53–
93, and 110–123 (19). The binding of heparin and copper co-
map to residues 53–93 and, interestingly, heparin binding
seems to be enhanced by copper ions (19, 20). Large and small
nucleic acids (21–24) also interact with PrP. It has been shown
that human, ovine, and murine PrPs possess nucleic acid bind-
ing and chaperoning activities similar to retroviral nucleocap-
sid protein (25, 26), and these properties are associated with
the unstructured N-terminal region of the protein (5, 10). Pre-
viously reported 2-OH aptamers raised against recombinant
hamster prion protein bound to a site between residues 23–52
within this nonspecific nucleic acid binding region (27). The
physiological implications of the interactions between PrP and
nucleic acid raise a number of questions that are still a matter
of speculation (23–26,28).
All of the published studies in which interactions between
PrP and nucleic acids have been demonstrated were done with
the -helix-rich form of PrP. To extend these studies we decided
to isolate nucleic acids that had high affinity for an infectious,
prion-containing material. We used purified, non-proteinase
K-treated scrapie-associated fibrils (SAF) prepared from the
263K strain as a target during in vitro selection for apatmer.
This SAF preparation is expected to include all variant PrP
conformations and PK sensitivities associated with infectivity
in this strain of prion, and should represent an appropriate
target to investigate the capacity of PrPSc as well as other
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proteins that co-purify with it to retrieve high affinity aptamer
ligands from a complex combinatorial RNA library.
We provide evidence that, like SAF, the -oligomer of PrP
bound to SAF-93 with at least 10-fold higher affinity than did
the -form. This differential affinity could be explained by the
existence of two binding sites within the PrP molecule: Site 1
lies within residues 23–110 in the unstructured N terminus
and is a nonspecific RNA binding site found in all forms of PrP.
The region between residues 90 and 110 forms a hinge region
that is occluded in the -rich form of PrP but becomes exposed
in the denatured form of PrP. Site 2 lies in the region C-
terminal of residue 110. This site is -sheet conformation-
specific and is not recognized by control RNAs. Taken together,
these data provide for the first time a specific ligand for a
disease conformation-associated site in a region of PrP critical
for conformational conversion. We also provide evidence that
SAF-93 inhibits the accumulation of PrPres in the cell-free
conversion assay under near physiological conditions.
MATERIALS AND METHODS
In Vitro Selection—All oligonucleotides used in this study were de-
scribed before (29). RNAs used for in vitro selection were produced by in
vitro transcription with T7 RNA polymerase in presence of 2-fluoro-
modified pyrimidine nucleotide triphosphates (TriLink BioTechnolo-
gies, Inc., San Diego, CA), together with unmodified purine ribonucle-
otides in an optimized transcription buffer (30). The 2-F-RNA
transcripts were purified by electrophoresis on a 10% (w/v) denaturing
polyacrylamide gel in TBE buffer. The pool of gel-purified 2-F-RNA
was heat denatured for 2 min at 95 °C in deionized and filter-sterilized
water, refolded for 10 min at room temperature in HMKN buffer (20 mM
Hepes pH 7.2, 10 mM MgCl2, and 50 mM KCl, 100 mM NaCl), before
being used for the selection process. The refolded 2-F-RNA pool (5
nmol) was incubated with SAF purified from approximately one-half of
a hamster brain, prepared as described below. Before each round of
selection an aliquot of SAF was sonicated in a cup-horn probe with three
pulses of 1 min each with an amplitude set at 40 and an output of 20
watts. The binding reaction was done at room temperature in HMKN
buffer for 4 h. After partitioning the binding reaction was centrifuged
for 1 h at 25,000  g at 10 °C. The amount of unbound 2-F-RNA in this
first supernatant was stored at 20 °C. In order to remove nonspecifi-
cally bound 2-F-RNA, the pellet containing 2-F-RNA-SAF complex
was washed three times with 100 l of HMKN buffer. The supernatants
from each wash were pooled with the first supernatant and the amount
of unbound 2-F-RNA determined by spectrophotometer (GeneQuant,
Amersham Biosciences). The bound RNA was converted to cDNA by
reverse transcription with Thermus thermophilus (Tth) DNA polymer-
ase at 70 °C for 20 min followed by 15 cycles of PCR amplification
following the protocol provided by the supplier (Promega). The resulting
PCR products were used as template for in vitro transcription to pro-
duce RNA for the next round of selection. The pool of RNA from round
7 was converted into DNA and cloned into pUC18 (29).
Preparation of Scrapie-associated Fibrils for Selection—SAF were
prepared from the brains of hamsters that were infected with the 263K
strain of scrapie (31). SAF were prepared without proteinase K treat-
ment as described by Hope et al. (32). This preparation should include
all variant PrP conformations and PK sensitivities associated with
infectivity in this strain of prion. The final pellet (P285) was washed
several times in water to remove traces of sarcosinate, before being
resuspended in HMKN buffer pH 7.2 containing 0.02% (w/v) azide and
stored at 4 °C.
Protein Preparation and Refolding—Truncated bovine PrPs, corre-
sponding to residues 90–230 and 110–230 (human numbering) with
His-tag at the N terminus were cloned, expressed, and purified as
described before (33). Full-length bovine PrP corresponding to residues
23–230 without any tag was obtained by PCR amplification of genomic
DNA and inserted as BglII-EcoRI restriction fragments into expression
plasmid pMG939 (34) and amplified in Escherichia coli K12 1B392/
pACYRIL, which overexpresses rare arginine, isoleucine, and leucine
tRNAs. Cultures were grown to saturation in Terrific Broth containing
100 g/ml ampicillin and 15 g/ml chloramphenicol at 30 °C then
diluted 400-fold. In late-log phase, expression of PrP was induced by
raising the temperature from 30 °C to 45 °C for 10 min, followed by
incubation at 42 °C for 5 h. The cells were then harvested by centrifu-
gation at 10 000  g for 15 min. The pellet was resuspended in ice-cold
lysis buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 2 mM phenylmeth-
ylsulfonyl fluoride, 10 g/ml lysozyme, 10 g/ml DNase I, 1 mg/ml
sodium deoxycholate) and incubated for 30 min at 37 °C. The solution
was then centrifuged at 10,000  g for 30 min, and the supernatant
discarded. The pellet was washed twice by resuspension in lysis buffer
with centrifugation at 10,000  g for 10 min between each wash.
Proteins in the pellet were dissolved by suspending it in buffer A (100
mM sodium phosphate, 10 mM Tris, pH 8.0, 8 M urea, and 10 mM
2-mercapthoethanol) and incubating for 30 min with gentle mixing. Cell
debris and insoluble material were removed by centrifugation at
15,000  g for 15 min. The supernatant was loaded onto a Ni-NTA-
Sepharose column (Qiagen Ltd.) pre-equilibrated with buffer A. After
washing the column with the same buffer, bound proteins were eluted
with buffer B (100 mM sodium phosphate, 10 mM Tris, pH 4.5, 8 M urea,
and 10 mM 2-mercaptoethanol). For further purification the eluate from
the column was diluted 1:2 with buffer C (50 mM Hepes pH 8.0, 8 M
urea, and 10 mM 2-mercapthoethanol) and loaded onto a cation ex-
change chromatography column, SP-Sepharose (Amersham Bio-
sciences). Recombinant PrP was eluted with buffer C supplemented
with 1.5 M NaCl. Eluted fractions of recombinant PrP were pooled, and
disulfide bonds were oxidized by stirring overnight in a 2:1 molar excess
of CuCl2. After oxidation, the protein solution was dialyzed against 50
mM sodium acetate, pH 5.5, 1 mM EDTA, with several changes of buffer.
Finally, the recombinant PrP was applied onto a size-exclusion chro-
matography column (Superdex 75 HR 10/30, Amersham Biosciences)
equilibrated and eluted with 50 mM sodium acetate, pH 5.5.
The purified PrPs were refolded into native -helical conformation or
-oligomeric isoform following the protocol described by Baskakov et al.
(35). Size exclusion chromatography were performed at room tempera-
ture with a flow rate of 1 ml/min using either a TSK-3000 or a BIOSEP-
S3000 HPLC column (300 7.8 mm) from Phenomenex, equilibrated in
20 mM sodium acetate, pH 3.7, 0.2 M NaCl, and 1 M urea. The main peak
corresponding to monomeric -helical rich form or -oligomer isoform of
PrP was manually collected and assessed by CD. The protein concen-
tration was determined spectrophotometrically using the molar extinc-
tion coefficient (280) of 19 890 M
1 cm1 for boPrP90–230, and of 62,280
M1 cm1 for boPrP23–230. The PrP peptide spanning the region 106–126
was synthesized, purified, and analyzed as described before (36).
Circular Dichroism—CD spectra were recorded with a Jasco J-720
CD spectrometer using the following parameters: scanning at 200 nm/
min, bandwidth of 2 nm, data spacing of 0.1 nm and using a 0.05- or
0.02-cm cuvette. Twenty individual scans were averaged, and the back-
ground spectra were subtracted.
Affinity of Monoclonal Aptamer for SAF—All RNAs used in this
study were 32P-labeled at the 5-end as described before (29). Scrapie-
associated fibrils from 263K strain of scrapie were prepared as de-
scribed above. The final pellet from one hamster brain was resuspended
in 200 l of HMKN buffer and submitted to ultrasonication. For homol-
ogous competition, 2 l of either proteinase K-treated or -untreated
SAF, were incubated with 7000 cpm of 32P-labeled monoclonal SAF-93
in HMKN buffer containing 1 g of tRNA and the mixture incubated for
1 h at room temperature. Cold homologous aptamer was added to each
tube in 2-fold increasing concentrations from 0.25 to 8192 nM and
incubated for 1 h. The displaced hot aptamer in each tube was sepa-
rated from the remaining bound aptamer by centrifugation at 25,000 
g and 10 °C for 20 min. The resulting pellet was resuspended in water,
and the amount of radiolabeled aptamer measured by Cerenkov count-
ing. Each competition experiment was done in triplicate, and the data
were analyzed by GraphPad PRISM.
Affinities of Monoclonal Aptamer for PrPs—Radiolabeled SAF-93 or
control aptamer 19 (10,000 cpm Cerenkov) were heat-denatured in
FIG. 1. Sequence alignment of isolated aptamers. The random regions from six SAF-aptamer clones were aligned using Pileup from GCG,
Wisconsin.
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water for 1 min at 95 °C, cool to room temperature for 3 min before
allowing it to refold in presence of 20 mM sodium acetate pH 5.2, 150 mM
NaCl, 50 mM KCl, and 5 mMMgCl2 for 10 min at room temperature. The
refolded aptamer was then mixed with a range of increasing concentra-
tions of PrP in various forms and lengths in presence of 1 M urea and 1
g of tRNA as nonspecific competitor in a total volume of 20 l. The
binding reactions were incubated for 2 h at room temperature. In order
to separate the free aptamer from PrP-aptamer complex we have used
Strataclean™ resin (Stratagene) that has the property to pull-down
proteins and RNA-protein complex by simple and quick centrifugation.
Three l of Strataclean™ resin (Stratagene) was added to the binding
reaction, and the mixture was vortexed and incubated for 1 min at room
temperature before spinning in a benchtop centrifuge at top speed for 1
min. The resulting supernatant was transferred to a fresh tube, and the
pellet washed with 20 l of binding buffer without tRNA. The super-
natant from the washed pellet was added to the previous supernatant,
this supernatant formed the unbound aptamer. The complex aptamer-
PrP remaining in the pellet was resuspended in 20 l of binding buffer.
The amount of radioactivity in both the supernatant, and the pellet was
measured by Cerenkov counting. The binding data were analyzed by
GraphPad Prism using a non-linear regression curve fitting and one
site binding hyperbola equation: Fraction bound  (Bmax  [PrP])/Kd 
[PrP].
Slot Blots—We have used Bio-Dot® SFmicrofiltration apparatus and
PVDF membrane (0.2-m pore size) from BioRad assembled following
the manufacturer’s instructions. 90 pmol of PrPs in various forms and
lengths were applied by vacuum onto the PVDF membrane that was
previously equilibrated in 20 mM sodium acetate buffer, pH 4.4. The
PVDF membrane containing PrPs was then incubated for 1 h in 15 ml
of blocking solution containing 5 Denhardt’s solution in HMNK buffer
pH 7.2 and 20 g/ml tRNA at room temperature. The blocking solution
was replaced with a fresh one and supplemented with 400,000 cpm
radiolabeled and refolded SAF-93 or control aptamer 19 and allowed to
incubate for 2 h or overnight at 25 °C inside a hybridization oven under
constant rolling. The membrane was then washed twice with 15 ml of
HMNK buffer pH 7.2, wrapped inside a saran film and exposed to
Storage phosphor screen for at least 2 h followed by scanning with the
Storm imaging system and the autoradiographs analyzed with Image-
Quant software from Molecular Dynamics.
SDS-PAGE and Western Blots—PrP proteins were separated under
denaturing and reducing conditions on SDS-PAGE (37) using 18% poly-
acrylamide precast Novex gels (Invitrogen). After electrophoresis the
gel was blotted (38) onto PVDF membrane and probed with either mAb
6H4 (Prionics) or mAb FH11 (TSE Resource center, IAH, Compton, UK)
followed by a secondary antibody conjugated to alkaline phosphatase
and detected with ECF substrate (Amersham Biosciences) using the
chemiluminescent mode on the Storm imaging system from Molecular
Dynamics. The detection with radiolabeled aptamers was performed as
described under “Slot Blot.”
Cell-free Conversion Assay—The cell-free conversion assay without
guanidinium chloride was as described by Kirby et al. (39) and based on
that used by Horiuchi and Caughey (40). Briefly PrPSc was sonicated
and 1 g incubated with 200 ng of [35S]shaPrP in conversion buffer
(50 mM citrate, pH 6.5, 50 mM KCl, 10 mM MgCl2, 100 mM NaCl, 0.1%
(v/v) Nonidet P-40) with or without SAF-93 or control RNA, for 24 h at
37 °C in a 20-l volume reaction. One-twentieth of the reaction was
removed for analysis without proteinase K treatment, and the remain-
ing was treated with 60 g/ml of proteinase K for 1 h at 37 °C. Protein-
ase K digestion was stopped by addition of Pefabloc to 1 mM. All samples
were precipitated with 20 g of bovine serum albumin and 4 volumes of
ice-cold methanol at 20 °C. The resulting pellet was boiled for 10 min
in SDS-sample buffer and analyzed by 15% SDS-PAGE, fixed, dried,
and exposed to film. Autoradiographs were quantified using Phoretix
Gel Analysis software.
RESULTS
Isolation of PrP-specific 2-F-RNA Aptamers—A DNA library
comprising a 49 nucleotide randomized region was synthesized.
In theory, this library could comprise 449  8  1028 distinct
sequences although in practice, only 1014 of these are sam-
pled during the selection process (41). The library was tran-
scribed to produce 2-F-pyrimidine-substituted RNA and sub-
jected to repeated cycles of in vitro selection for transcripts that
bound to insoluble non-PK-treated PrPSc fibrils isolated from
the brains of 263K scrapie-infected hamsters. PrP-binding 2-
F-substituted nucleic acids became a significant fraction of the
population by selection round 3, and the pool from round 7 was
cloned as cDNA.
The sequences of the clones encoding ligands for PrP show
that they probably derived from distinct members of the initial
library (see Fig. 1). Some stretches of weak sequence homology
between the six clones might reflect some convergence of struc-
tural features. In this study we present the data obtained from
investigating the interaction between SAF-93 and PrP protein
in various lengths and conformations.
Affinities of Aptamer for PrP Forms—The first step toward
the characterization of the selected monoclonal 2-F-SAF-
aptamers was to determine the strength of their binding to SAF
used as a target during the in vitro selection. We have used a
homologous competition binding assay in which we have meas-
ured the binding of a single concentration of 32P-end-labeled
SAF-93 to SAF preparation in presence of an increasing con-
centration of the same unlabeled aptamer (Fig. 2). The fitting of
homlogous competition data to a one site binding model
(GraphPad Prism Software, Inc.) gave an estimated Kd of
23.4  1.2 nM without proteinase K (PK)-treatment of SAF and
a Kd of 26.9  1.1 nM against PK-treated SAF. These data
indicated that the aptamer binding site lay in the PK-resistant
core of disease isoform PrP, comprising residues 90–230.
The biochemical and biophysical properties associated with
the SAF material made it difficult to perform routine investi-
gations in order to gain better understanding of the interaction
between our aptamer and the disease-associated form of PrP.
Therefore we decided to use purified bacterially-expressed re-
combinant bovine PrP of various lengths that had been refolded
into -helical conformation or -oligomer form with an intact
disulfide bridge as described by Baskakov et al. (35). The
-form and -form (Fig. 3A) of bovine PrP eluted from the SEC
with retention times very similar to those published for mouse
PrP89–231 (35, 42). The peaks that eluted at 7.19 and 9.06 min
were collected and analyzed by CD (Fig. 3B) and found indeed
to correspond to - and -form of PrP90–230, respectively. Sim-
ilar results were obtained with the full-length PrP23–230 (data
not shown).
We used the forms of recombinant bovine PrP described
above in an equilibrium binding assay with radiolabeled
SAF-93 in parallel with a radiolabeled control aptamer SA-19
that was isolated against streptavidin (29) in order to deter-
mine the equilibrium binding constant of the interactions (Fig.
4). The binding affinity of SAF-93 for the truncated -PrP90–230
FIG. 2. Affinity of aptamer SAF-93 for proteinase K-treated
and untreated scrapie-associated fibrils. Unlabeled SAF-93 was
used as a competitor of the formation of complex between 32P-end-
labeled SAF-93 and SAF. The normalized data were fitted to the equa-
tion: Fraction bound  ([Hot93])/([Hot93]  [Cold93]  Kd) using non-
linear curve fitting with GraphPad Prism software.
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and full-length -PrP23–230 was found to be 32.2 nM (Fig. 3C)
and 16.0 nM (Fig. 3D), respectively. Significantly, these affini-
ties were close to those determined for the PK-treated and
-untreated SAF (see above), indicating that SAF-93 recognized
a binding site that was common between SAF and in vitro
refolded -form PrPs and that the aptatope was conserved
between these two species.
When the affinity of SAF-93 for -PrP90–230 (Fig. 3E) and
-PrP23–230 (Fig. 3F) was measured, the affinity was found
to be 10- and 5-fold less than that measured for the -form
FIG. 3.Refolding of recombinant bovine PrPs and affinity measurment. A, SEC profile of recombinant PrPs that were refolded into either
-form (thin line) or oxidized-form (bold line). B, far UV CD spectra of the main peaks collected from SEC. The CD spectra were recorded in 20 mM
sodium acetate, pH 3.7 containing 200 mM NaCl and 1 M urea, and confirmed the -helix (continuous line) and the -sheet (short-dashed line)
conformations of PrP90–230. The protein concentration was 4.3 and 6.8 M for - and -forms, respectively. C–F, aptamer SAF-93 (filled squares)
and aptamer SA-19 (open circles, control) were 5-end-labeled to high specific activity and mixed with varying concentrations of oxidized-PrP
90–230,
oxidized-PrP
23–230, -PrP90–230, and -PrP23–230, respectively. PrP-bound and unbound aptamer were partitioned using Strataclean resin and the
fraction bound determined as described. Data were fitted to a hyperbolic function by non-linear curve fitting method of GraphPad PRISM. The
result of the fitting is represented by solid line. The x-axis in panel F has been split and rescaled to better highlight the differences in affinities
between - and -form PrP.
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PrP90–230 and -form PrP23–230, respectively. When compared
with SAF-93, the control aptamer SA-19 has an affinity that
was at least 10-fold lower for both conformations and lengths of
PrPs (Fig. 3, C–F).
As a complementary approach, the binding of SAF-93 to the
same PrPs was assayed under native conditions by slot blot-
ting. The results revealed that preserving the conformation of
the aptamer binding site was essential for maintaining the
discriminatory power between - and -form PrPs, and that
was most marked for PrP90–230 (Fig. 4, A and B). SAF-93 could
only bind to PrP90–230 in its -form, while the binding to -form
was virtually abolished (Fig. 4, A and B). Under these condi-
tions, SAF-93 bound equally well to - and -form PrP23–230
(Fig. 4, A and B). Both approaches led to qualitatively similar
conclusions. First, the aptamer binding site was occluded in
-PrP90–230 and only became accessible to the aptamer in
-PrP90–230. Second, the conformation-specific binding site for
SAF-93 resided downstream of residue 90. Third, the binding
site for SAF-93 in the unstructured N-terminal segment up-
stream of residue 90 was conformationally nonspecific and
could represent a region of PrP with high nucleic acid binding
propensity.
Mapping the Binding Site of SAF-93 on PrP—Since the PK
treatment of SAF and the truncation of recombinant bovine
PrP did not affect the binding properties of the aptamer, it was
clear that a binding site resided within the PK resistant core of
PrP (residues 90–230). In attempting to define the binding site
more precisely, we were helped by the fortuitous appearance of
a defined degradation product of PrP in Western blotting ex-
periments (see Fig. 5).
Coomassie Blue staining of the gel (Fig. 5A) showed one
major band for -PrP23–230 with the expected molecular mass of
23.6 kDa, whereas the -PrP90–230 revealed two bands of ap-
proximately equal intensities: a band with a molecular mass of
15.9 kDa as one would expect from the bovine PrP residues
90–230, and another band with a lower molecular mass (Fig.
5A). Mass spectrometry analysis of the protein sample in solu-
tion revealed that it contained both PrP90–233 and PrP110–230
(data not shown). In the absence of other signals we concluded
with 99% confidence that the fragment 110–230 was what
caused the second band on the gel. Similar proteolysis digestion
has been reported for recombinant murine prion protein (20,
43). When the blot derived from this gel was probed with
[32P]SAF-93 (Fig. 5B), two clear bands were detected that cor-
responded to PrP23–230 and PrP90–230. The probing with 32P-
control aptamer, SA-19, revealed a similar detection pattern,
but with significantly lower intensities than those obtained
with SAF-93 (see Fig. 5C). In fact, the intensity of the displayed
digital picture had to be substantially increased in order to
make the two bands visible. The identity of the two bands
detected with SAF-93 was further confirmed by probing similar
blots with mAb 6H4 (Fig. 5D) and as expected, PrP90–230 was
not detected by mAb FH11 (Fig. 5E). Most significantly, the
band that corresponded to PrP110–230 was not detected by SAF-
aptamer 93, indicating that an essential part of the aptamer
binding site spanned residues 90–110. In order to further char-
acterize the interaction between SAF-93 and PrP110–230, the
latter was cloned, expressed, purified, and characterized by
SDS-PAGE (Fig. 6A). We confirmed that under denaturing
conditions and using North-Western blot assay SAF-93 did not
bind to PrP110–230 (Fig. 6B) nor did control aptamer SA-19 (Fig.
6C), whereas the reactivity of this protein toward mAb 6H4
was maintained as expected (Fig. 6D). Importantly, when
PrP110–230 was refolded into -form as before, we found that
the binding affinity toward SAF-93 was restored to values
(Fig. 6E) very close to those calculated for -PrP23–230 and
-PrP90–230 (see Fig. 3, C and D for comparison). When
PrP110–230 was folded into the -form its interaction with
SAF-93 was abolished (Fig. 6F). The control aptamer SA-19
bound only weakly to -PrP110–230 (Fig. 6E) and not at all to
-PrP110–230 (Fig. 6F). These data provided strong evidence for
the existence of a conformation-specific SAF-93 binding site
downstream of residue 110. This conformation-specific apta-
tope is not recognized by the aptamer when the PrP110–230 is
denatured or folded into the -form.
Numerous studies have indicated that the region 106–126,
just upstream of the first -sheet, is a conformationally flexible
part of the protein (36, 44, 45) and is neurotoxic (46–50).
Because of the overlap between this “neurotoxic peptide” region
and that defined as containing an SAF-93 binding site, we
decided to test whether SAF-93 could bind to peptide
PrP106–126. By adjusting the buffer conditions, we could fold
this peptide into a -form, or retain it in a random coil confor-
mation (see Fig. 7A). The affinity of SAF-93 was found to be
very similar between the unstructured (Fig. 7B) and the -form
(Fig. 7C) of PrP106–126, in the order of 400 nM, which is very
close to the affinity value measured for -PrP90–230 determined
above. However, as the affinity for -forms PrP had been found
to be in the 20–30-nM range (see above), this indicates that the
region 106–126 might contain only part of the aptamer binding
site or that the folding of the peptide into -form did not
FIG. 4. Binding of SAF-93 to folded PrP derivatives. A, 90 pmol
of -PrP23–230, -PrP90–230, oxidized-PrP
23–230, and oxidized-PrP
90–230
were applied in duplicate onto PVDF membrane using the Slot blot
apparatus (Bio-Rad) and the proteins detected with either [32P]SAF-93
or with [32P]SA-19 as control aptamer. The intensity of the displayed
digital picture had to be increased in order to make the bands visible.
However, the quantitation analysis has been done on the original un-
modified picture. The bands were then detected by Storage Phosphor
technology. B, the bands were analyzed with ImageQuant software.
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faithfully represent the folding of this region in the context of
PrPSc.
Inhibition of Cell-free Conversion of PrP by Aptamer—The
preferential binding of SAF-93 to the disease-related -form
PrP prompted us to investigate the capacity of this artificial
ligand to interfere with the conformational switch that leads to
the accumulation of PrPres. We have used the cell-free conver-
sion system under near-physiological conditions in order to give
more biological relevance to the assay as a model for conver-
sion. In this study, recombinant hamster PrP was radiolabeled
during expression, purified from bacteria and refolded in vitro
(39). [35S]ShaPrP was incubated in the presence of unlabeled
PrPSc isolated from 263K scrapie-infected hamster brains, with
or without control RNA or with increasing concentrations of
SAF-93 in a guanidine-free conversion buffer at 37 °C for 24 h.
Following proteinase K digestion, SDS-PAGE analysis and au-
toradiography (Fig. 8A), the intensity of the band at17.4 kDa,
representing the PK-resistant core of [35S]ShaPrPres, de-
creased with increasing amounts of SAF-93. Even at the high-
est concentration, the unselected 2-F-RNA library produced no
significant inhibition of conversion (Fig. 8A). Similar results
were obtained when the control SA-19 aptamer (29) was used
instead of the unselected RNA library (data not shown). These
data showed that there was a specific SAF-93-dependent inhi-
bition of the accumulation of PrPres protein. The average IC50
titer was estimated from the dose response graph in Fig. 8B
and found to be around 40 nM for SAF-93.
DISCUSSION
Here we describe the isolation of novel nucleic acid ligands or
aptamers for PrP, the key protein in the pathogenesis and the
transmission of vCJD, BSE, and other TSEs. Because of the
high propensity of recombinant PrP to interact with nucleic
acid via its unstructured N-terminal domain, it was of para-
mount importance to discriminate between specific and non-
specific interactions. The first indication of specificity of
aptamer SAF-93 came from the homologous competition assay.
The fact that binding affinity was not affected by proteinase K
treatment of SAF material, suggested that the aptatope lay in
the PK-resistant core of PrP, comprising the 141 amino acids in
the C-terminal portion of the protein, from residue 90 to 230.
Moreover, the binding affinity measured for -oligomer PrP
spanning residues 90–230 was very close to that of SAF mate-
rial that has been treated with proteinase K. These suggest
conformational similarities between SAF and -oligomer
PrP90–230. In the light of the recently published data by
Baskakov et al. (35), it is very important to stress at this point
that these structural similarities might be just subtle enough
to account for the existence of a common -sheet rich aptatope
between SAF material and -oligomer PrP, even though the
latter is not considered to be on the kinetic pathway for amyloid
formation and cannot be regarded as a substructure of the
fibrillar form (35). Because PrPSc and PrPC both maintain the
disulfide bridge (51) we believe that it was more relevant to use
the non-reduced PrP to generate the -oligomer form. However,
we found that SAF-93 maintained the same binding affinity
against -form PrP with no disulfide bridge (33).2 The simple
explanation for this is that the absence of the disulfide bridge
does not affect local folding into a -sheet of the region down-
stream of residue 90 where SAF-93 aptatope occurs. In agree-
ment with this explanation is the fact that all structures of
recPrPs showed that the disulfide bridge is located between
helix B and helix C, which seemed to maintain their global
conformation in the plausible models for the structure of
PrPSc (52).
The molecular basis for the preferential recognition of -oli-
gomer PrP by SAF-93 is still unclear, but our data reinforce
and extend previous reports that RNA interactions with pro-
teins are generally more favorable with -sheet than -helix
(53). We were fully aware of the fact that the analysis of the
binding data with an equation that governed one binding site
might not reflect the true complexity of the interaction between
aptamers and PrP. However, we have analyzed the binding
data between SAF-93 and -PrP23–230 with an equation that
described the existence of two independent binding sites. We
found an affinity value for the nonspecific site (1) of 8 M while
the conformation-specific site (2) had an affinity value of 16 nM;
a value that remained identical to that obtained by fitting the
data to one binding site equation. This reinforces the idea that
the binding of SAF-93 to -form PrPs 23–230, 90–230, and
110–230 could be accounted for by the existence of only the
conformation-specific and low affinity site (2).
2 A. Rhie, N. Sayer, P. Disterer, W. James, and A. Tahiri-Alaoui,
unpublished data.
FIG. 5. Binding of SAF-93 to dena-
tured PrP derivatives. A–E, recombi-
nant bovine PrPs were analyzed on 18%
SDS-PAGE and then either stained with
Coomassie Blue, or blotted onto PVDF
membrane and probed with [32P]SAF-93,
[32P]SA-19 (control aptamer), mAb 6H4,
or mAb FH11, respectively. The band
framed in panel A, is a proteolysis frag-
ment that was confirmed by mass spec-
trometry to correspond to residues
110–230.
Conformationally Selective Prion-binding Aptamers39702
FIG. 6. Binding affinity of SAF-93 to PrP110–230. A–D, a derivative
of recombinant bovine PrP corresponding to residues 110–230 was
characterized as described in Fig. 5. PrP23–230 and PrP90–230 were
analyzed in parallel for direct comparison. E and F, the fraction
of [32P]SAF-93 (filled squares) or 32P-SA-19 (open circles, control
aptamer) bound by increasing concentration of oxidized-PrP
110–230 and
-PrP110–230, respectively were determined as before. Data were fitted
to a hyperbolic function by non-linear curve fitting method of GraphPad
PRISM. The result of the fitting is represented by solid line. The x-axis
in panel F has been split and rescaled to better highlight the differences
in affinities between - and -form PrP.
FIG. 7. Binding affinity to unstructured and -form PrP106–126.
A, far UV CD spectra of PrP peptide 106–126 refolded into -form
(short-dashed line) after incubation for at least 2 h in 10 mM potassium
phosphate pH 8.0 and mixing it with 20 mM sodium acetate, pH 4.8,
containing 100 mM NaCl, 50 mM KCl and 10 mM MgCl2; the final pH
was 5.4. These buffer conditions were compatible with those used to
determine the binding affinity as well as to obtain a peptide population
that is highly populated with a -form. The unstructured form of
PrP106–126 (continuous line) was simply obtained by incubating the
peptide in 20 mM sodium acetate, pH 5.4, containing 100 mM NaCl, 50
mM KCl, and 10 mM MgCl2. The peptide concentration was 140 M. B
and C, [32P]SAF-93 (filled squares) or [32P]SA-19 (open circles, control
aptamer) bound to increasing concentration of unstructured-PrP106–126,
-PrP106–126, respectively, were determined as before. Data were fitted
to a hyperbolic function by non-linear curve fitting method of GraphPad
PRISM. The result of the fitting is represented by solid line.
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The data from the mapping of the aptamer binding site onto
PrP conformations provided a basis to explain the aptamer-de-
pendent inhibition effect on the conversion of [35S]ShaPrPsen to
PrPres. Although the molecular mechanisms of this conversion
are as yet to be elucidated, direct interaction between PrPSc
and [35S]ShaPrPsen is critically important. Two non-exclusive
mechanisms could explain the inhibition of the conversion by
aptamer. First, the aptamer could bind directly to the PrPSc
used as a template for conversion, therefore preventing any
direct and critical contact between [35S]ShaPrPsen and PrPSc.
Second, and by virtue of its high affinity to the -rich PrP, the
aptamer might bind to any escaped de novo formed -rich PrP
and thereby stall the conversion.
Antibody mapping has indicated sites of interaction between
PrPsen and PrPres. One or more of these areas were adjacent to
the C terminus in the three-dimensional structure of PrPsen
(40, 54). One such surface contains residues 119–138 and oth-
ers contain residues 165–174 and 206–223. Antibodies that
bind to these areas are capable of interfering with PrPres accu-
mulation (40). The inability of antibodies recognizing residues
90–104 and 106–115 to inhibit PrPres formation has been at-
tributed to conformational rearrangements occurring during
the process of conversion that might induce the antibody to
dissociate (40). Indeed, many biochemical and spectroscopic
studies concord to suggest that the region 90–124 undergoes a
major conformational change during the formation of PrPres (2,
5, 36) and (55–57). Intriguingly, the site we suggest for SAF-93
binding lies in a region defined recently by us to be involved in
competing intra-chain interactions that lead to -sheet-rich
fibril formation in vitro (36). It is possible that SAF-93 is able
to inhibit the fibril-promoting interactions between residues
104–122 and 129–141 that such studies with isolated peptides
have indicated.
Very recently, Proske et al. (58) have isolated an aptamer to
a peptide spanning residues 90–129 of PrP, which has the
ability to reduce the level of PrPSc accumulation in persistently
prion-infected neuroblastoma cells. It is intriguing that there is
a potential overlap between the binding site of our SAF-93 and
their aptamer DP7 (58). It should be noted, however, that
region 90–129 includes part of the N-terminal, conformation-
ally non-selective nucleic acid binding region of PrP (this study)
and that these aptamers do not share any similarity in either
the primary or the secondary structures. It remains to be
determined whether DP7 aptamer exhibits any differential
affinity between -helix rich and -oligomer PrP, as it was
selected using a short peptide of undefined structure, rather
than infectious material, as employed here. Furthermore,
aptamer DP7 comprises pyryimidine 2-amino, 2-deoxyribo-
nucleotides, rather than the 2-F modifications employed in
this work. It is known that different substitutions at the 2-
position result in changes in binding activity, probably by in-
fluencing the functional folding of RNA (29). It is significant
that both aptamers were able to interfere with the conversion
of PrPC into PrPSc. Any comparison between the potency of the
two aptamers in this regard must be made with caution, as the
in vitro conversion assays were fundamentally different. Nev-
ertheless, there is reason to believe that aptamer SAF-93,
described here, may be the more potent inhibitor as it produced
2-fold inhibition of conversion at 40 nM, compared with 700
nM, for comparable effects with DP7 (58).
Our data strengthen the existing literature about the intrin-
sic property of the -helical form of PrP to interact with nucleic
acids in general and RNA in particular, and extend the high
affinity of the prion protein for RNA to the -form disease-
related PrP. These properties should be investigated further in
order to gain more insight into the putative physiological role of
PrP in RNAmetabolism (25, 26, 28) and should provide ways to
trap PrP in a disease-inactive conformation that might cleanse
physiological fluids.
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